SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor has recently been reporte...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li, Xiaochen Yu, Bei Sun and Liming Chen Tags: Original investigation Source Type: research
More News: Cardiology | Cardiomyopathy | Cardiovascular | Diabetes | Empagliflozin | Endocrinology | Heart | Jardiance | SGLT2 Inhibitors | Sodium